|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
The Novacea story, Millenium Pharmaceuticals potential and Satraplatin's impact.
A diversified holding of Alzheimer's drug developers could pay off big.
The S&P fails to set a new record, leading some to ask 'Is this it?' Plus, Adam Feuerstein on Elan's big move and ASCO leaks.
The S&P fails to set a new high, leading some to declare a 'top' is in. Plus, Adam Feuerstein on Elan's big news and ASCO leaks.
Dendreon's big date, the good and bad on Biomira and a Cougar worth stalking.
Study results show that the drug might have promise in treating multiple sclerosis.
TheStreet.com Ratings gives health care and biotech funds a clean bill of health.
Investors who haven't found a pure play may have to move up the food chain.
Traders will zero in on consumer-level inflation, as well as earnings reports from major retailers.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.